NCT07087834

Brief Summary

Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. According to GLOBOCAN 2022 data, more than 51% of all cancer cases worldwide occur in men. The three most common types of cancer in men are lung cancer, prostate cancer, and colorectal cancer. Increasing awareness, attitudes, and knowledge levels regarding cancer screenings, especially for preventable diseases, will increase participation in screening programs. Increased knowledge levels will translate into positive health behaviors. This study will be conducted as a randomized controlled trial to determine the effect of the Cancer Screenings Education for Men (CASEM) intervention on men's perceptions, attitudes, and knowledge regarding cancer screening programs. Research data will be collected at a public institution between September 2025 and September 2026. The study sample will consist of a total of 78 male individuals, including 39 experimental and 39 control groups that meet the inclusion criteria. Male individuals will be assigned to the experimental and control groups using stratified randomization. The Individual Identification Form, Cancer Screening Perception Scale, Cancer Screening Attitude Scale, and Cancer Screening Knowledge Scale will be used. IBM SPSS 29.0 software will be used to analyze the data obtained from the study. This study will be an important one that addresses Turkey's future vision within the scope of the Twelfth Development Plans and supports the goals and policy measures of the development plan. In addition, our study serves the Sustainable Development Goals, which are among the most important global goals in the context of sustainability. It is expected to have implications for health practices and planning.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 4, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

July 28, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

January 21, 2026

Status Verified

August 1, 2025

Enrollment Period

29 days

First QC Date

July 4, 2025

Last Update Submit

January 18, 2026

Conditions

Keywords

Men's HealthEarly Detection of CancerScreening

Outcome Measures

Primary Outcomes (3)

  • The change in the cancer screening perception of the experimental group according to the Cancer Screening Perception Scale scores at the end of the first and third month

    It is a 26-item scale developed by Mahmood et al. (2016). Its validity and reliability in Turkish were established by Bozkurt and Yılmaz (2024). The scale items generally cover. The scale has five sub-factors: "Perceived Severity, Perceived Sensitivity, Perceived Benefits, Perceived Barriers, and Action Cues." The scale is a 6-point Likert scale (1 = Strongly disagree, 6 = Strongly agree). To prevent confusion, there is no "undecided" option. The scale is not aggregatable, and each sub-dimension in the scale is evaluated separately.

    3 months

  • The change in the cancer screening attitude of the experimental group according to the Cancer Screening Attitude Scale scores at the end of the first and third month

    The scale was developed by Yıldırım-Öztürk and colleagues (2020). The scale consists of 24 items and a single dimension. The scale is a five-point Likert scale. The items comprising the scale are answered on a scale ranging from 5 to 1, as follows: "5: I completely agree, 4: I somewhat agree, 3: I neither agree nor disagree, 2: I somewhat disagree, 1: I completely disagree." The scale is suitable for use on women and men aged 30-70 who are at least literate and do not have cognitive, visual, or orthopedic impairments that would prevent them from completing the scale.

    3 months

  • The change in the cancer screening knowledge of the experimental group according to the Cancer Screening Knowledge Scale scores at the end of the first and third month

    The scale was developed by Yıldırım-Öztürk and Uyar (2023). The scale consists of 25 items and 3 subscales. The subscales of the scale have not been specifically named. The first subscale of the scale consists of 10 items (items 8, 17-23, 25, and 28), the second subscale consists of 9 items (items 4, 5, 7, 10, 12, 13, 15, 16, and 27), and the third subscale has 6 items (items 1-3, 9, 11, 24). The scale is a three-point rating scale. The scale is answered on a scale from 1 to 3, with "1: Correct, 2: Incorrect, 3: I don't know." When calculating the scale score, "True" responses are scored as 1 point, while 'False' and "I don't know" responses are scored as 0 points. The lowest possible score on the scale is 0, and the highest possible score is 25. When calculating the scale score, the three items with negative meanings (Items 2, 11, and 24) must be reverse-coded. No cutoff point has been established for the scale score.

    3 months

Secondary Outcomes (1)

  • Individuals' status regarding cancer screening in the final test conducted at the end of the third month after education

    3 months

Study Arms (2)

Experimental group

EXPERIMENTAL
Other: CASEM (Cancer Screenings Education for Men)

Control Group

NO INTERVENTION

Interventions

Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session. Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo

Experimental group

Eligibility Criteria

Age30 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be included in the study, participants must meet all of the following criteria:
  • Be 30 years of age or older at the time of the study,
  • Be at least literate,
  • Have no cognitive, visual, or orthopedic impairments that would prevent them from completing the questionnaires,
  • Be able to speak and understand Turkish,
  • Have no previous history of cancer diagnosis or cancer treatment,
  • Agree to participate in the study.

You may not qualify if:

  • Participants are excluded from the study if they meet any of the following criteria:
  • Having previously had cancer and undergone cancer treatment,
  • Not currently employed at the institution (e.g., on temporary assignment),
  • Refusing to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pamukkale University

Denizli, 20160, Turkey (Türkiye)

Location

MeSH Terms

Interventions

Menogaril

Intervention Hierarchy (Ancestors)

NogalamycinDaunorubicinAnthracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic CompoundsAminoglycosidesGlycosidesCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The final tests (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session. Content and Materials of the Training to be Provided to the Experimental Group The CASEM intervention will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. CASEM covers basic information about cancer, common types of cancer among men, screening
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

July 4, 2025

First Posted

July 28, 2025

Study Start

September 1, 2025

Primary Completion

September 30, 2025

Study Completion

April 30, 2026

Last Updated

January 21, 2026

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will share

All collected IPD will share.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
starting 1 months after publication
Access Criteria
all people access

Locations